Table 2.
Normal | Abnormal physical exam | Abnormal Cycles | Abnormal physical exam& abnormal cycles | ||
---|---|---|---|---|---|
Group I (N=42*) | Group II (N=41*) | Group III (N=15*) | Group IV (N=22*) | P value (ANOVA) | |
T, mean, ng/dL (SD) | 65.6 (43.5) | 62.0 (28.4) | 77.6 (70.4) | 99.3(71.2) | <0.051,** |
SHBG, mean, ug/dL (SD) | 1.8 (0.7) | 1.5 (0.8) | 1.5 (0.8) | 0.8 (0.3) | <0.012,*** |
FAI, mean (SD) | 4.3 (4.0) | 5.8 (5.0) | 6.2 (5.3) | 17.3 (24.7) | <0.013,** |
Δ 4 A, mean, ng/dL (SD) | 294.0 (124.0) | 311.6 (114.1) | 343.7 (177.4) | 446.5 (187.1) | <0.014, ** |
LH, mean, IU/L (SD) | 6.2 (8.2) | 4.8 (3.0) | 9.3 (6.4) | 9.2 (4.8) | <0.015, ** |
LH:FSH ratio (SD) | 1.2 (1.0) | 1.1 (1.1) | 2.8 (4.8) | 1.9 (1.1) | <0.016, ** |
Fasting glucose, median (range) (mg/dL) | 84.0 (55–99) | 84.0(55–101) | 85.0(58–91) | 83.5 (70–101) | 0.979 |
GIR, median (range) | 6.6 (2.4–21) | 4.7 (1.4–17.8) | 5.4 (3.8–22.8) | 3.9 (1.2–21.5) | <0.017,*** |
SD – standard deviation GIR – Glucose: Insulin Ratio
for SHBG, Δ4A, LH, and FSH, Ns are 41, 41, 15, and 21 for GI, GII, GIII, and GIV, respectively, as the androgen levels in 2 samples were not done; for T and FAI, N is 36, 36, 14, and 19 for GI, GII, GIII, and GIV, respectively, as testosterone levels in 15 samples were not done; for glucose and insulin levels all 120 subjects were tested.
p<0.05 for significantly positive trend from group I to IV by Kendall’s Tau_b and Spearman’s rho.
p<0.01 for significantly negative trend from group I to IV by Kendall’s Tau_b and Spearman’s rho.
Post-hoc Scheffe (group II vs. IV, p=0.08):
Post-hoc Scheffe (group I vs. IV, p<0.01, group II vs. IV, p<0.01, group III vs IV, p<0.05)
Post-hoc Scheffe (group I vs. IV, II vs IV, III vs IV, p<0.01)
Post-hoc Scheffe (group I vs. IV, p<0.01, group II vs. IV, p<0.01)
Post-hoc Scheffe (group II vs. IV, p<0.06)
Post-hoc Scheffe (group II vs. III, p=0.04)
Kruskal-Wallis, Mann-Whitney (group I vs II, I vs IV, III vs IV, p<0.01)